Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ramoutsaki, 2002, Pain relief and sedation in Roman Byzantine texts: Mandragoras officinarum, Hyoscyamos niger and Atropa belladonna, Int Congr Ser, 1242, 43, 10.1016/S0531-5131(02)00699-4
Santoro, 2011, Development of the concept of pain in history, J Nephrol, 24, S133, 10.5301/JN.2011.6481
Medicines, 2015, The selection and use of essential medicines, vii
Pert, 1973, Opiate receptor: demonstration in nervous tissue, Science, 179, 1011, 10.1126/science.179.4077.1011
Martin, 2003, Acute antinociceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones, Eur J Neurosci, 17, 701, 10.1046/j.1460-9568.2003.02482.x
Matthes, 1996, Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene, Nature, 383, 819, 10.1038/383819a0
Janssen, 1963, The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawal reflex in rats, Arzneimittelforschung, 13, 502
Heel, 1979, Buprenorphine: a review of its pharmacological properties and therapeutic efficacy, Drugs, 17, 81, 10.2165/00003495-197917020-00001
Osterloh, 1978, General pharmacological studies on tramadol, a potent analgetic agent (author's transl), Arzneimittelforschung, 28, 135
Raffa, 1994, G-protein antisense oligodeoxyribonucleotides and mu-opioid supraspinal antinociception, Eur J Pharmacol, 258, R5, 10.1016/0014-2999(94)90073-6
Sanchez-Blazquez, 2001, Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia, Brain Res Bull, 54, 229, 10.1016/S0361-9230(00)00448-2
Marker, 2005, Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids, J Neurosci, 25, 3551, 10.1523/JNEUROSCI.4899-04.2005
Bourinet, 1996, Determinants of the G protein-dependent opioid modulation of neuronal calcium channels, Proc Natl Acad Sci U S A, 93, 1486, 10.1073/pnas.93.4.1486
Bohn, 2000, Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence, Nature, 408, 720, 10.1038/35047086
Raehal, 2005, Morphine side effects in beta-arrestin 2 knockout mice, J Pharmacol Exp Ther, 314, 1195, 10.1124/jpet.105.087254
Groer, 2011, Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation, J Biol Chem, 286, 31731, 10.1074/jbc.M111.248310
Bohn, 1999, Enhanced morphine analgesia in mice lacking beta-arrestin 2, Science, 286, 2495, 10.1126/science.286.5449.2495
Shenoy, 2001, Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin, Science, 294, 1307, 10.1126/science.1063866
Shenoy, 2009, Beta-arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2, Proc Natl Acad Sci U S A, 106, 6650, 10.1073/pnas.0901083106
Zheng, 2011, Beta-arrestin2 plays permissive roles in the inhibitory activities of RGS9-2 on G protein-coupled receptors by maintaining RGS9-2 in the open conformation, Mol Cell Biol, 31, 4887, 10.1128/MCB.05690-11
Shenoy, 2006, Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor, J Biol Chem, 281, 1261, 10.1074/jbc.M506576200
Luttrell, 1999, Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes, Science, 283, 655, 10.1126/science.283.5402.655
Guo, 2008, The beta-arrestin-2 scaffold protein promotes c-Jun N-terminal kinase-3 activation by binding to its nonconserved N terminus, J Biol Chem, 283, 15903, 10.1074/jbc.M710006200
Bruchas, 2006, Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes, J Biol Chem, 281, 18081, 10.1074/jbc.M513640200
Oakley, 2000, Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors, J Biol Chem, 275, 17201, 10.1074/jbc.M910348199
Bohn, 2004, Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery, Mol Pharmacol, 66, 106, 10.1124/mol.66.1.106
Kenakin, 2011, Functional selectivity and biased receptor signaling, J Pharmacol Exp Ther, 336, 296, 10.1124/jpet.110.173948
Kenakin, 2013, Signalling bias in new drug discovery: detection, quantification and therapeutic impact, Nat Rev Drug Discov, 12, 205, 10.1038/nrd3954
Wisler, 2014, Recent developments in biased agonism, Curr Opin Cell Biol, 27, 18, 10.1016/j.ceb.2013.10.008
Gentry, 2015, Novel allosteric modulators of G protein-coupled receptors, J Biol Chem, 290, 19478, 10.1074/jbc.R115.662759
Violin, 2007, Beta-arrestin-biased ligands at seven-transmembrane receptors, Trends Pharmacol Sci, 28, 416, 10.1016/j.tips.2007.06.006
Zocher, 2012, Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human beta2 adrenergic receptor, Structure, 20, 1391, 10.1016/j.str.2012.05.010
Gaieb, 2016, Molecular mechanism of biased ligand conformational changes in CC chemokine receptor 7, J Chem Inf Model, 10.1021/acs.jcim.6b00367
Manglik, 2015, Structural insights into the dynamic process of beta2-adrenergic receptor signaling, Cell, 161, 1101, 10.1016/j.cell.2015.04.043
Liu, 2012, Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR, Science, 335, 1106, 10.1126/science.1215802
Black, 1983, Operational models of pharmacological agonism, Proc R Soc Lond B Biol Sci, 220, 141, 10.1098/rspb.1983.0093
Ehlert, 2008, On the analysis of ligand-directed signaling at G protein-coupled receptors, Naunyn Schmiedebergs Arch Pharmacol, 377, 549, 10.1007/s00210-008-0260-4
Thompson, 2016, Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor, Biochem Pharmacol, 113, 70, 10.1016/j.bcp.2016.05.014
Gesty-Palmer, 2009, A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation, Sci Transl Med, 1, 1ra1, 10.1126/scitranslmed.3000071
Wisler, 2007, A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling, Proc Natl Acad Sci U S A, 104, 16657, 10.1073/pnas.0707936104
Kim, 2008, Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation, Proc Natl Acad Sci U S A, 105, 14555, 10.1073/pnas.0804745105
Violin, 2010, Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance, J Pharmacol Exp Ther, 335, 572, 10.1124/jpet.110.173005
Park, 2016, Effects of beta-arrestin-biased dopamine D2 receptor ligands on schizophrenia-like behavior in hypoglutamatergic mice, Neuropsychopharmacology, 41, 704, 10.1038/npp.2015.196
Groer, 2007, An opioid agonist that does not induce mu-opioid receptor—arrestin interactions or receptor internalization, Mol Pharmacol, 71, 549, 10.1124/mol.106.028258
Lamb, 2012, Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology, Drug Alcohol Depend, 121, 181, 10.1016/j.drugalcdep.2011.10.026
Chen, 2013, Structure-activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain, J Med Chem, 56, 8019, 10.1021/jm4010829
DeWire, 2013, A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine, J Pharmacol Exp Ther, 344, 708, 10.1124/jpet.112.201616
Manglik, 2016, Structure-based discovery of opioid analgesics with reduced side effects, Nature, 1
Bohn, 2003, Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice, J Neurosci, 23, 10265, 10.1523/JNEUROSCI.23-32-10265.2003
Varadi, 2016, Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism which do not recruit beta-arrestin-2, J Med Chem, 10.1021/acs.jmedchem.6b00748
Zadina, 2016, Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine, Neuropharmacology, 105, 215, 10.1016/j.neuropharm.2015.12.024
Li, 2009, Improvement of morphine-mediated analgesia by inhibition of beta-arrestin 2 expression in mice periaqueductal gray matter, Int J Mol Sci, 10, 954, 10.3390/ijms10030954
Jiang, 2006, Decreased morphine analgesia in rat overexpressing beta-arrestin 2 at periaqueductal gray, Neurosci Lett, 400, 150, 10.1016/j.neulet.2006.02.071
Lalley, 2014, CrossTalk opposing view: the pre-Bötzinger complex is not essential for respiratory depression following systemic administration of opioid analgesics, J Physiol, 592, 1163, 10.1113/jphysiol.2013.258830
Montandon, 2014, CrossTalk proposal: the preBötzinger complex is essential for the respiratory depression following systemic administration of opioid analgesics, J Physiol, 592, 1159, 10.1113/jphysiol.2013.261974
Wang, 1992, The co-existence of biogenic amines and neuropeptides in the type I cells of the cat carotid body, Neuroscience, 47, 473, 10.1016/0306-4522(92)90261-Y
Wharton, 1980, Enkephalin-, VIP- and substance P-like immunoreactivity in the carotid body, Nature, 284, 269, 10.1038/284269a0
Nagi, 2014, Kir3 channel signaling complexes: focus on opioid receptor signaling, Front Cell Neurosci, 8, 10.3389/fncel.2014.00186
Montandon, 2016, G-protein-gated inwardly rectifying potassium channels modulate respiratory depression by opioids, Anesthesiology, 124, 641, 10.1097/ALN.0000000000000984
Akbarali, 2014, Site and mechanism of morphine tolerance in the gastrointestinal tract, Neurogastroenterol Motil, 26, 1361, 10.1111/nmo.12443
Wood, 2004, Function of opioids in the enteric nervous system, Neurogastroenterol Motil, 16, 17, 10.1111/j.1743-3150.2004.00554.x
Sugahara, 1992, Effects of intrathecal and intraperitoneal morphine on gastrointestinal motility in the rat, Eur J Anaesthesiol, 9, 341
Nelson, 2016, Opioid-induced constipation: advances and clinical guidance, Ther Adv Chronic Dis, 7, 121, 10.1177/2040622315627801
Mori, 2013, Mechanisms that underlie mu-opioid receptor agonist-induced constipation: differential involvement of mu-opioid receptor sites and responsible regions, J Pharmacol Exp Ther, 347, 91, 10.1124/jpet.113.204313
Kang, 2012, The role of beta-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract, J Pharmacol Exp Ther, 340, 567, 10.1124/jpet.111.186320
Galligan, 2014, Molecular physiology of enteric opioid receptors, Am J Gastroenterol Suppl, 2, 17, 10.1038/ajgsup.2014.5
Bohn, 2000, Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells, J Neurochem, 74, 574, 10.1046/j.1471-4159.2000.740574.x
Gan, 2014, Consensus guidelines for the management of postoperative nausea and vomiting, Anesth Analg, 118, 85, 10.1213/ANE.0000000000000002
Ronen, 2016, Smart respiratory monitoring: clinical development and validation of the IPI (Integrated Pulmonary Index) algorithm, J Clin Monit Comput
Overdyk, 2016, Association of opioids and sedatives with increased risk of in-hospital cardiopulmonary arrest from an administrative database, PLOS ONE, 11, e0150214, 10.1371/journal.pone.0150214
Soergel, 2014, First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers, J Clin Pharmacol, 54, 351, 10.1002/jcph.207
Soergel, 2014, Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers, Pain, 155, 1829, 10.1016/j.pain.2014.06.011
Singla, 2016, A randomized, placebo-and active-controlled phase 2b abdominoplasty study investigating oliceridine(TRV130), a novel μ receptor G protein pathway selective (μ-GPS) modulator
BreakthroughTherapies, www.focr.org/breakthrough-therapies.